Thievon has more than 20 years of professional experience in strategic product launches, marketing, commercialization, sales penetration and distribution leadership. Most recently, he served as president and chief executive officer of MiddleBrook Pharmaceuticals. In this capacity, he helped build the company from an 18-person start-up to a 450-person organization before the company's assets were acquired by Victory Pharma.

Prior to leading MiddleBrook Pharmaceuticals, Thievon was executive vice president of commercial operations for Adams Respiratory Therapeutics over a nine-year span. He built Adams' marketing platform and led the launch of Mucinex®, growing it to a $450 million brand before the company was sold to Reckitt Benckiser.

Mylan's President Heather Bresch commented: "I am extremely pleased to welcome John as our new leader of Mylan's specialty business. John's extensive experience growing a branded pharmaceutical business from the ground up and proven track record launching highly successful pharmaceutical brands, like Mucinex, is invaluable as we continue to build on our specialty business. Dey has been and continues to be a very valuable asset and important growth driver for Mylan, evidenced by the strong performance of this business. John's appointment demonstrates our continued commitment to invest in Dey and strengthen what we have in place in order to support the continued success of this business into the future."

Thievon commented: "I am thrilled to be joining Mylan as Dey's new president. I am excited about the potential of Dey's existing product portfolio and the introduction of new products. The momentum behind this business is a result of impressive execution by the strong team already in place at Dey and I look forward to working alongside this team to maximize Dey's growth potential."

Thievon began his career as a management trainee and sales representative for Ortho Pharmaceuticals after graduating with a bachelor's degree in marketing from Pace University, New York, N.Y. He subsequently spent four years at IMS Health, where he developed his expertise in leveraging market data to generate informed and innovative business plans.

About MylanMylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.